Souhaitez-vous accéder aux communiqués récents ?

Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targetsThe agreement - OBT's second high-profile pharma...

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Orelabrutinib has demonstrated remarkable efficacy and safety in multiple lymphoma studies, including MZL, MCL, CLL/SLL, PCNSL and DLBCL.

Issued on behalf of Aleen Inc. VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Last month marked a major turning point as Google launched Gemini...

Xcellbio and Culture Biosciences partner to integrate AVATAR Foundry with Console, enabling real-time data, remote monitoring, and AI-driven optimization.

Transpire Bio today announced that the U.S. FDA has completed a Pre-Approval Inspection (PAI) with a Voluntary Action Indicated (VAI) classification

Pow.Bio, the pioneer in AI-enabled continuous fermentation technology, and Bühler Group, the global solution provider for food, feed, and advanced material

Boston, Dec. 09, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Separation Systems for Commercial Biotechnology” is projected to grow from $32.5 billion in 2025 to $45.1...

New data show 100% (6/6) objective response rate (ORR) with EO2463 in previously untreated patients with follicular lymphoma needing treatment in combination with rituximab (SIDNEY Cohort 3)Of the 6...

Vera Therapeutics announces proposed public offering of Class A common stock.